Walleye Capital’s Amphastar Pharmaceuticals AMPH Stock Holding History

Walleye Capital’s Portfolio AMPH Stock Details AMPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-8,666	Closed	-$322K	–	4206
2024 Q4	$322K	Buy	+8,666	New	+$396K	﹤0.01%	3361
2024 Q3	–	Sell	-5,017	Closed	-$201K	–	5225
2024 Q2	$201K	Buy	+5,017	New	+$208K	﹤0.01%	4301
2023 Q4	–	Sell	-39,854	Closed	-$1.83M	–	4902
2023 Q3	$1.83M	Buy	+39,854	New	+$2.17M	﹤0.01%	1806
2023 Q2	–	Sell	-23,231	Closed	-$871K	–	4274
2023 Q1	$871K	Buy	+23,231	New	+$762K	0.01%	1271
2022 Q1	–	Sell	-30,267	Closed	-$705K	–	2266
2021 Q4	$705K	Buy	+30,267	New	+$619K	0.02%	778

Other funds holding AMPH

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

EIP

Epoch Investment Partners New York $17.6B AUM 34.17% 1-Year Est. Return

BTW

Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Walleye Capital's AMPH Position: Q1 2025 in Review

Walleye Capital sold out of Amphastar Pharmaceuticals (AMPH) in Q1 2025, closing a stake of 8,666 shares — an estimated $322K sold.

Walleye Capital first reported a position in AMPH in Q4 2021 and held it in 5 quarters. The position peaked at $1.83M in Q3 2023. 241 funds tracked by Wall St. Rank hold AMPH as of Q1 2025.

Walleye Capital reported no remaining Amphastar Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
Walleye Capital sold 8,666 Amphastar Pharmaceuticals shares in Q1 2025, an estimated $322K.
Walleye Capital first reported a position in Amphastar Pharmaceuticals in Q4 2021 and held it in 5 quarters.
Walleye Capital's Amphastar Pharmaceuticals position peaked at $1.83M in Q3 2023.
241 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q1 2025.

Based on Walleye Capital's 13F filing for Q1 2025, filed 14 May 2025.